1. Government-enterprise collaboration, jointly fulfilling the innovation agreement
On the morning of April 10, 2025, a delegation led by Sun Xianlong, Director of the Standing Committee of the People's Congress of Huzhou City, Gao Shenghua, Director of the Standing Committee of the People's Congress of Changxing County, Zhuang Zhongjie, Secretary of the Party Committee of Hongqiao Town, and Shen Shuming, Chairman of the Standing Committee of the People's Congress of Hongqiao Town, visited Zhejiang Longye Biotechnology Co., Ltd. (hereinafter referred to as "Longye Biotechnology"). They came to understand the company's innovative achievements and development plans in the field of biopharmaceuticals. The company's chairman, Luo Fuquan, led the core team to warmly receive them. The two sides had in-depth exchanges around the theme of "Science and Technology Empowering Health, Innovation Driven Development" and jointly looked forward to the future picture of Huzhou's biopharmaceutical industry.
During the research process, the leaders visited the company's R&D center, production base, and the area for displaying achievements in turn, and listened in detail to the report on the company's core technology, product pipeline, market layout, and industrialization progress. In the fields of infectious disease diagnosis and treatment, microecological health, and tumor precision screening, Longyue Biotechnology has shown its "hardcore" scientific research strength and clinical translation ability, and has received high attention and recognition from the leaders.
(From left to right: Shen Shumin, Pan Jianping, Gao Shenghua, Sun Xianlong, Luo Fuquan, Zhuang Zhongjie)
2. leadership message: Painting a new chapter of the industry with innovation as the brush.
During the research symposium, the leadership team highly praised the development achievements of Longyue Biologics: "As a biopharmaceutical enterprise that has grown up in Huzhou, Longyue Biologics has shown three highlights: a 'problem-oriented' research mindset focused on clinical pain points, an innovative model of deep integration of medical, academic, research, and industrial sectors, and a strategic vision to root in Huzhou and radiate globally."
In terms of the company's future planning, the leaders have put forward earnest expectations:
1. Strengthening technological barriers: Continuously increase R&D investment, accelerate the registration process for Class III medical devices, and create "Huzhou-made" pharmaceutical products with international competitiveness;
2. Deepening industrial synergy: Leverage the leading role of key enterprises to coordinate the local upstream and downstream industrial chains, and help Huzhou form a biopharmaceutical industry cluster;
3. Fulfilling social responsibilities: Guided by the needs of the people, promote the universal access to high-quality products, and let the achievements of scientific and technological innovation benefit more citizens.
"Enabling health with technology and repaying Huzhou with innovation." As Chairman Luo Fuquan said, Longyue Biotechnology will always adhere to "Medical Heart", guided by clinical value and supported by policy, to write a new chapter in the high-quality development of the biopharmaceutical industry in the new journey of government-enterprise collaboration!
This research injects new momentum into government-enterprise cooperation. We look forward to Longyue Biotechnology taking strides forward on the road of scientific and technological innovation and serving the country through industry, contributing more strength to "Healthy Huzhou" and "Healthy China"!
